XOMA公司（XOMA Corp）与武田制药（Takeda）近日宣布，双方已就实验性药物Mezagitamab达成一项战略性的版税共享交易。此次合作不仅涉及对现有协议的修订，更通过创新性的版税分配机制深化了双方在药物开发领域的伙伴关系。该举措有望为两家企业带来更灵活的利益共享模式，同时加速Mezagitamab的临床推进进程。
XOMA公司（XOMA Corp）与武田制药（Takeda）近日宣布，双方已就实验性药物Mezagitamab达成一项战略性的版税共享交易。此次合作不仅涉及对现有协议的修订，更通过创新性的版税分配机制深化了双方在药物开发领域的伙伴关系。该举措有望为两家企业带来更灵活的利益共享模式，同时加速Mezagitamab的临床推进进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.